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Abstract
Introduction Our aim was to study and possibly improve
the clinical management of potential drug–drug interactions
(pDDIs) in hospitalized patients by specific interventions.
Methods During the initial period, inpatients on three
medical wards were screened for major and moderate
pDDIs using the interaction screening program Pharma-
vista. During the second period, patients at discharge were
screened similarly. After assessment of the detected pDDIs
for clinical relevance, written recommendations and/or
information about the pDDIs were sent to the treating
physicians. Feedback from the physicians and implementa-
tion of the recommendations were analyzed.
Results During the initial period, 502 inpatients were
exposed to 567 pDDIs, of which 419 (74%) were judged
to be clinically relevant. Three hundred and forty-nine
substantiated recommendations and 70 simple information
leaflets were handed out to the physicians. Eighty percent
(278 of 349) of the recommendations were accepted and
implemented. During the second period, 792 patients at
hospital discharge were exposed to 392 pDDIs, of which
258 (66%) were judged to be clinically relevant. Two
hundred and forty-seven substantiated recommendations
and 11 simple information leaflets were sent to the
physicians. Seventy-three percent (180 of 247) of the
recommendations were accepted. At hospital discharge, 47
of 71 interventions recommending checkable medication
changes were implemented. One year after hospital dis-
charge, 11 of 13 checked medication changes were still in
place.
Conclusions Clinically relevant pDDIs are common in
patients on medical wards, and their management can be
influenced by providing substantiated recommendations to
physicians. Most changes in medication following such
recommendations are still in place 1 year after discharge.
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Introduction
Medication errors, adverse drug events (ADEs), and
adverse drug reactions (ADRs) are common and clinically
important problems. ADEs and ADRs are associated with
considerable morbidity and mortality [1–12]. Potential
drug–drug interactions (pDDIs) are important risk factors
for ADRs, as shown, for instance, for rhabdomyolysis
associated with the use of statins [13]. According to a
recently published study, 1% of all hospital admissions
were caused by drug–drug interactions (DDIs), cor-
responding to 16% of all patients admitted with ADRs
[8]. In a review of nine studies about ADRs, the authors
reported that ADRs due to DDIs caused 2.8% of all hospital
admissions [14]. In recent years, major advances in our
understanding regarding DDIs could be observed, particu-
larly in the molecular mechanism by which drugs interact.
In contrast, our ability to appropriately apply this informa-
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tion to specific patients has not progressed with the same
velocity, and many patients continue to suffer from ADRs
associated with DDIs.
Changes in medication at the transition point from
outpatient to inpatient care and vice versa may increase
the frequency of drug-related problems such as pDDIs [10,
15–17]. In our own study of the prevalence of pDDIs
during hospital stay (Vonbach B, unpublished observation),
47% of all pDDIs at discharge were created by medication
changes during hospitalization. Furthermore, several defi-
ciencies were detected regarding the clinical management
of pDDIs.
The aims of this study were therefore to analyze pDDIs
and to find ways to improve their clinical management by
appropriate interventions during hospitalization and at
hospital discharge.
Methods
Patients and data collection
The intervention study was conducted at the Cantonal
Hospital of Baden. The protocol of the study had
previously been approved by the local ethics committee.
The hospital is a 400-bed teaching institution serving a
population of approximately 250,000 inhabitants. The
Clinic of Medicine was not equipped with a computerized
physician order entry (CPOE) and, therefore, no automatic
DDI order check was available.
Two separate groups of patients were studied at different
occasions. Between February and May 2005, patients
admitted to three medical wards were included into the
first study (intervention study during hospitalization).
Information on drugs prescribed during hospitalization
was retrieved from clinical records and collected on a fixed
day once a week and once per patient. Between June and
October 2005, patients to be discharged from three wards
were included in the second study (intervention study at
hospital discharge). This intervention was performed as
soon as the date of discharge was known, when the patients
were still in the hospital. Information on drugs prescribed at
discharge was obtained from the hospital discharge letters
on the day of discharge.
Demographic information (age and sex), length of
hospital stay, main diagnosis [according to the International
Classification of Diseases (ICD-10)] and the number of
additional diagnoses were obtained from clinical records.
Classification of pDDIs and interventions
Medication was screened for pDDIs by a clinical pharmacist
(PV) using the drug interaction screening program Pharma-
vista [18]. This drug interaction program originates from the
ABDA-Datenbank published by the Bundesvereinigung
Deutscher Apothekerverbände (Federal Organization of
German Pharmacist Associations). The program was
chosen based on our own evaluation of nine drug
interaction screening programs, revealing that Pharmavista
is the most suitable widely available drug–drug interaction
program for the Swiss drug market [19]. The program
classifies severities of DDIs into five categories: (1) major1,
(2) moderate2, (3) minor3, (4) insignificant4, and (5)
unidentified source5.
After screening, pDDIs classified as major and moderate
according to Pharmavista were judged for clinical rele-
vance. Pharmavista provides a judgment for clinical
relevance, which was accepted in most cases. If the clinical
pharmacist disagreed with this judgment, she had to
compare it with the judgment in Stockley’s Dug Interactions
[20]. In the case of an agreement between Stockley’s and
Pharmavista, this judgment was accepted. In the case of a
disagreement, the clinical pharmacist had to discuss the
problem with one of the coauthors (AD, JHB, SK) until an
agreement had been achieved. For pDDIs judged to be
clinically relevant, written recommendations concerning the
clinical management of the pDDI were prepared for the
treating physicians. In addition to these recommendations, a
leaflet based on the information contained in Pharmavista
about the mechanism of the pDDI, possible ADRs, and the
clinical management of the pDDI and ADRs was prepared
and sent to the treating physicians. Physicians were asked
to give written feedback regarding acceptance or rejection
of the recommendations. In addition, in the second part of
the study (intervention at hospital discharge), physicians
were asked to assess the clinical relevance of the pDDI
themselves.
Implementation of the recommendations during hospi-
talization was verified by investigating the medication
prescribed at hospital discharge, which was checked for
changes according to the recommendations. Concerning the
interventions at hospital discharge, short-term implementa-
tion was verified by investigating the medication prescribed
at hospital discharge. Long-term implementation was
1 Major interactions: May be life threatening, or permanent damage
may be induced. Such drugs should not be administered together.
2 Moderate interactions: Frequently cause therapeutic difficulties and
may even cause harm. Combinations may be administered, however,
if patients are monitored carefully.
3 Minor interactions: Are associated with increased or reduced drug
effects, but these alterations, in general, do not cause harm and can be
tolerated.
4 Insignificant interactions: Cause mainly no or only unimportant
effects, and no special action is required.
5 Unidentified source: For such interactions, no medical literature is
available. Their clinical relevance is therefore unclear.
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investigated by asking the general practitioners of randomly
selected patients for details about the current medication
1 year after hospital discharge.
Statistical analysis
Descriptive data were expressed as means with corresponding
95% confidence intervals (CIs), as medians with ranges, or as
proportions. Data were analyzed with R for Windows version
2.2.0 (R Development Core Team, 2005, R Foundation for
Statistical Computing, Vienna, Austria).
Results
Patient characteristics and dropouts
Between February and May 2005, 539 patients were enrolled
for the intervention study during hospitalization. Of these, 37
(7%) patients were excluded (31 patients died during
hospitalization, and six patients were excluded due to gaps
in their medical history). The median time between hospital
admission and registration of the drugs prescribed was 5 days
(mean 5.1 days, 95% CI 4.7–5.6 days). Between June and
October 2005, data concerning 826 patients were recorded at
the end of hospitalization for the intervention study at hospital
discharge. Patient characteristics are displayed in Table 1.
Prescribed drugs and prevalence of pDDIs
The number of drugs prescribed per patient, the drug pairs
analyzed, and the prevalence ofmajor and moderate pDDIs are
presented in Table 2. Fewer patients (n=502) were analyzed
in the intervention study during hospitalization than in the
study at hospital discharge (n=792). Due to a higher number
of drugs prescribed to inpatients than at hospital discharge
(median n=11 vs. n=6 drugs per patient, respectively), the
total number of major and moderate pDDIs and the number
of pDDIs per patient was nevertheless higher during
hospitalization (567 pDDIs, 1.13 pDDIs per patient) than at
hospital discharge (392 pDDIs, 0.49 pDDIs per patient).
Interventions performed
During the intervention period for inpatients, 419 pDDIs
(74% out of the 567 major and moderate pDDIs) were
Table 1 Characteristics of
patients included in the two
arms of the study
Characteristics Intervention during
hospitalization
(n=502)
Intervention at
hospital discharge
(n=792)
Age - years Mean 68.4 66.5
95% confidence interval 67.2–69.7 65.3–67.6
Median 71 69
Range 17–96 17–99
Sex - no. (%) Male 231 (46) 404 (51)
Female 271 (54) 388 (49)
Length of hospital
stay - days
Mean 13.0 9.3
95% confidence interval 12.1–13.9 8.6–9.9
Median 10 7
Range 1–91 1–72
Number of diagnoses Mean 4.3 4.5
95% confidence interval 4.1–4.5 4.3–4.6
Median 4 4
Range 1–16 1–15
Main diagnoses
(according to
ICD-10) -
no. (%)
Diseases of the circulatory system 137 (27.3) 221 (27.9)
Diseases of the respiratory system 78 (15.5) 54 (6.8)
Diseases of the digestive system 52 (10.4) 109 (13.8)
Neoplasms 42 (8.4) 61 (7.7)
Symptoms, signs, or abnormal
clinical or laboratory findings
not classified elsewhere
36 (7.2) 22 (2.8)
Factors influencing health status
and contact with health services
14 (2.8) 45 (5.7)
Diseases of the nervous system 25 (5.0) 44 (5.6)
Diseases of the musculoskeletal
system and connective tissue
20 (4.0) 42 (5.3)
Other (<5%) 98 (19.5) 194 (24.5)
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judged to be clinically relevant (see Fig. 1). For 349 pDDIs,
recommendations including an information leaflet about the
pDDI were provided. For 70 additional cases, simply the
respective Pharmavista general information leaflet was
handed out to the treating physicians.
Regarding the intervention period at hospital discharge,
258 pDDIs were judged to be clinically relevant (66% out
of 392 major and moderate pDDIs; see Fig. 1). For 247
pDDIs, recommendations including information about the
pDDI and for 11 pDDIs, Pharmavista information leaflets
only were delivered to the treating physicians.
Table 3 shows a summary of the recommendations.
Among the 419 interventions during hospital stay, 48 (11%)
implied withdrawal or replacement of a drug. Four recom-
mendations (1%) implied temporal withdrawal (pausing) of a
drug and three (0.7%) the prescription of an additional drug.
At hospital discharge, withdrawal or replacement of a drug
was recommended in 29 (11%) of the 258 interventions.
During the hospitalization intervention period, 130 additional
recommendations concerning the pDDI and possible ADRs
were provided directly to the general practitioners treating the
patients (111) and/or to certain patients themselves (25).
During the intervention period at hospital discharge, the
hospital physicians were asked to transmit the recommenda-
tions to the general practitioners. In addition, 17 advices about
pDDIs and possible ADRs were given directly to the patients
during this period of the study.
In 218 (38% of 567) cases of pDDIs during hospitali-
zation and 145 (37% of 392) instances of pDDIs at hospital
discharge, no specific recommendation was provided. In
148 (68% of 218) pDDIs during hospitalization and in 63
(43% of 145) pDDIs at hospital discharge, the reason to
omit a recommendation was due to a difference in judgment
regarding clinical relevance of the pDDI between the
intervention team and Pharmavista. In such cases, this
drug–drug interaction had to be listed as clinically not
relevant in Stockley [20]. For example, the combinations
insulin and cardioselective beta-blockers, topical β2-
sympathomimetics and cardioselective beta-blockers, low
molecular weight heparin and low dose aspirin, or topical
corticosteroids and diuretics are all classified as moderate
pDDIs by Pharmavista, but they were not considered to be
clinically relevant by the intervention team. Other reasons
for omitting recommendations were the existence of
specific patient variables (e.g., time-limited therapy), or
the management of the pDDI had already been initiated by
the treating physician.
Acceptance of the interventions and assessment
of the clinical relevance of pDDIs by treating physicians
As shown in Fig. 1, 80% (278 of 349) of the recommen-
dations provided during the intervention period for inpa-
tients and 73% (180 of 247) of the recommendations during
the intervention period at hospital discharge were accepted
and executed by the hospital physicians. No feedback was
obtained for 12% (42) and 13% (32), respectively, of the
recommendations provided. Eight percent (29) and 14%
(35) of the recommendations, respectively, were not
accepted by the treating physicians. Specifically, three
recommendations concerning major pDDIs were not accepted
during hospitalization. All three recommendations concerned
the prescription of a noncardioselective beta-blocker and
β2-sympathomimetics as inhalative antiasthmatic drugs. At
hospital discharge, two major pDDIs (a noncardioselective
beta-blocker combined with an inhalativeβ2-sympathomimetic
antiasthmatic drug and an α2-sympathomimetic drug—
Table 2 Number of drugs and drug pairs analyzed per patient and
prevalence of major and moderate potential drug–drug interactions
(pDDIs) [95% confidence interval (CI)]
Parameters Intervention
during
hospitalization
(n=502)
Intervention
at hospital
discharge
(n=792)
Number of
drugs (drugs
prescribed
“as required”
excluded)
Mean
(95% CI)
7.8 (7.5–8.1) 5.7 (5.5–5.9)
Median
(range)
7 (0–21) 5 (0–18)
Number of
drugs
prescribed
“as required”
Mean
(95% CI)
3.7 (3.6–3.8) 0.4 (0.4–0.3)
Median
(range)
3 (0–12) 0 (0–5)
Total number
of drugs
(“as required”
included)
Mean
(95% CI)
11. (11.1–11.9) 6.1 (5.9–6.3)
Median
(range)
11 (1–26) 6 (0–18)
Number of
drug pairs
(“as required”
included)
Mean
(95% CI)
70.1
(65.3–74.9)
20.8
(19.3–22.4)
Median
(range)
55 (0–325) 15 (0–153)
Number of
patients with
≥1 major pDDI
No. (%) 22 (4.4) 6 (0.8)
95% CI (%) 2.6–6.2 0.15–1.36
Number of
patients with
≥1 major or
moderate pDDI
No. (%) 284 (56.6) 243 (30.7)
95% CI (%) 52.2–61.0 27.5–33.9
Number of major
pDDIs per patient
Mean
(95% CI)
0.05
(0.03–0.08)
0.01
(0.00–0.01)
Median
(range)
0 (0–3) 0 (0–1)
Number of major
or moderate
pDDIs per patient
Mean
(95% CI)
1.13
(0.98–1.27)
0.49
(0.43–0.56)
Median
(range)
1 (0–13) 0 (0–7)
Drugs prescribed “as required” are included in the analysis
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clonidine—combined with a noncardioselective beta-blocker)
were not accepted.
Out of 258 major and moderate pDDIs at hospital
discharge, 209 (81%) were assessed as clinically relevant
by the treating physicians, 15 (6%) as not clinically
relevant, and for 34 (13%) pDDIs, no feedback was
obtained. Two major pDDIs (a non-cardioselective beta-
blocker combined with a β2-sympathomimetic as an
inhalative antiasthmatic drug, and a potassium salt com-
bined with a potassium-sparing diuretic) were assessed as
clinically not relevant by the physicians.
Verification of the implementation by the treating
physicians
Verification of the implementation of the recommendations
at hospital discharge was only possible in cases where drug
regimen changes (withdrawal, replacement, or pausing of a
drug or prescription of an additional drug) had been
recommended. Drugs prescribed “as required” were ex-
cluded from this analysis. Eighty-five percent of such
recommendations (60 of 71) had initially been accepted (no
feedback: four; refusal of the recommendation: seven). Of
those, 47 recommendations had been implemented at
discharge, corresponding to 66% of all recommendations
and to 78% of the accepted recommendations. The second
verification, 1 year after hospital discharge, was performed
in 16 randomly selected patients. Two patients died during
the year after discharge, and one patient had changed his
general practitioner and could therefore not be located. In
85% (11 of 13 recommendations that could be judged), the
medication changes according to the recommendation were
still in place.
Discussion
Several studies have shown that appropriate interventions
by health professionals can reduce prescribing errors [21–
23]. According to Leape et al. [22], the presence of a
Fig. 1 Interventions in patients with major or moderate potential drug–drug interactions (pDDIs) and feedback concerning acceptance and
implementation of the recommendations by the treating physicians. Intervention periods are (1) during hospitalization and (2) at hospital discharge
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pharmacist on rounds in a medical intensive care unit is
associated with a substantially lower rate of ADEs
associated with prescribing errors. In this study, the rate
of ADEs associated with wrong prescription decreased by
66%: from 10.4 per 1,000 patient-days (95% CI 7–14)
before to 3.5 (95% CI 1–5) after the intervention [22].
Furthermore, a direct association between the availability of
clinical pharmacy services with the frequency of medica-
tion errors was demonstrated by the evaluation of almost
half a million medication errors in 1,081 US hospitals [23].
An analysis of the causes of preventable prescribing errors
revealed that clinical pharmacists could play an important
role in the prevention of prescribing errors; for instance, in
supplying appropriate information and in monitoring
prescriptions to detect errors at this stage [24]. Potential
DDIs should be identified and dealt with by a close
collaboration between treating physicians and clinical
pharmacists, preferably at the moment of drug prescription
[25]. On the other hand, a recent study revealed that
systematic review of medications by a clinical pharmacol-
Table 3 Type of recommen-
dation to avoid major and
moderate potential drug–drug
interactions (pDDIs)
Intervention during
hospitalization (total
number of interventions
419)
Intervention at hospital
discharge (total number
of interventions 258)
Withdrawal of a
drug – no. (%)
5 (1.2) 5 (1.9)
Withdrawal of a drug
prescribed “as required”
- no. (%)
13 (3.1) 0 (0.0)
Replacement of a drug by
another drug – no. (%)
30 (7.2) 24 (9.3)
Replacement of a drug by
another drug or to pause
a drug - no. (%)
4 (1.0) 0 (0.0)
Prescription of an
additional drug – no. (%)
3 (0.7) 0 (0.0)
Change of the drug
application time – no. (%)
18 (4.5) 35 (13.6)
Fixation of the end of
therapy - no. (%)
6 (1.4) 1 (0.4)
Fixation of the maximal
dose - no. (%)
10 (2.4) 1 (0.4)
Monitoring of possible
adverse drug reactions
- no. (%)
24 (5.7) 38 (14.7)
Monitoring of the renal
function - no. (%)
22 (5.3) 12 (4.6)
Monitoring of the blood
pressure - no. (%)
17 (4.1) 18 (7.0)
Monitoring of the
international normalized
ratio value - no. (%)
62 (14.8) 42 (16.3)
Monitoring of the potassium
serum level - no. (%)
77 (18.4) 39 (15.1)
Monitoring of the drug
blood or serum level
- no. (%)
6 (1.4) 15 (5.8)
Monitoring of the glucose
blood level - no. (%)
24 (5.7) 6 (2.3)
Verification of the indication
for a drug - no. (%)
5 (1.2) 4 (1.6)
Information provided about
the pDDI only - no. (%)
70 (16.7) 11 (4.3)
Other measures (<1.0%)
- no. (%)
6 (1.0) 6 (2.3)
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ogist with special knowledge in DDIs and ADRs did not
reduce drug-related morbidity or mortality [26]. One
explanation for this finding is that pDDIs only rarely result
in ADRs [11]. Nevertheless, ADRs associated with DDIs
can be of high clinical importance [8, 13], justifying close
monitoring of medications for pDDIs.
Acceptance of recommendations regarding management
of pDDIs by treating physicians in our study (80% during
the intervention period in inpatients and 73% during the
intervention period at discharge) is comparable to the
degree of acceptance of 63% reported in an intervention
study in which written advice was provided [26]. Accep-
tance of more than 90% of the interventions was reported
when direct (oral) communication between treating physi-
cians and clinical pharmacists was possible [22, 27]. We
assume that improvements regarding the degree of accep-
tance of well-documented and easily manageable pDDIs are
possible. For example, three of 23 recommendations
concerning interactions between statins and cytochrome
P450-3A4-inhibiting drugs to replace the statin by a
noninteracting statin or to pause statin therapy during an
anti-infectious therapy with clarithromycin were rejected by
treating physicians. Reasons mentioned for these refusals
were either the absence of clinical relevance and/or the rarity
of clinical ADRs associated with this pDDI. The frequency
of rhabdomyolysis in patients treated with a statin without a
DDI is in the range of 1:10,000 patient years [28]. In patients
treated with a statin and with a pDDI associated with an
increase in the statin serum concentration, the frequency of
rhabdomyolysis is estimated to increase by a factor of ten,
reaching 1:1,000 patient years [29]. Although rhabdomyol-
ysis is still a rare event even in the presence of a pDDI, it is
our opinion that such pDDIs should be avoided due to the
severity of rhabdomyolysis, which can be fatal [13].
Similarly, three of eight recommendations concerning
the interaction between polyvalent cations and quinolone
antibacterials to postpone application time of the polyvalent
cation were also refused by treating physicians. It is well
established that concomitant administration of a polyvalent
cation can dramatically impair the absorption of quinolones
[30]. Such combinations should therefore be avoided.
Clinical management of pDDIs mostly implies monitor-
ing of either symptoms of a possible ADR or of laboratory
parameters. Only in 11% of the cases was modification of
the prescription recommended. These findings concur with
the results of a study analyzing the nature and management
of pDDI alerts in Dutch community pharmacies, where 9%
of all actions contained prescription modification [31].
Drug interaction screening programs may be helpful
tools to check prescriptions for DDIs. Although automated
order checks offer possible benefits for patient care, the
effect of such real-time warnings remains to be compre-
hensively assessed [32]. Previous research suggests that
above a certain threshold, more warnings are ignored or
overridden rather than followed [33, 34]. A reduction in
overrides was achieved by displaying only critical to high-
severity alerts [35].
In our study, about one third of all moderate pDDIs
detected by Pharmavista were judged to be not clinically
relevant. This corresponds well with our evaluation study
[19], which revealed a positive predictive value of 0.67 for
Pharmavista using Stockley’s Drug Interactions as the gold
standard [20]. Other approaches to classify pDDIs, e.g., by
considering not only the severity of possible ADRs, may
possibly increase acceptance by treating physicians. An
interesting approach was proposed by a Dutch working
group [36], which defined four core parameters, namely,
degree of evidence for the existence of a pDDI, clinical
relevance and incidence of ADRs associated with the
pDDI, and presence of additional risk factors associated
with the development of an ADR. A management-orientat-
ed algorithm containing four decision layers (severity,
manageability, risk/benefit assessment, and patient-related
risk factors associated with a given pDDI) was proposed by
another group [37]. Similarly, the OpeRational ClassificA-
tion (ORCA) system [38] takes into account the potential
severity of the ADR due to a DDI, the factors known to
increase or decrease the risk for the development of an
ADR, and the existence of management alternatives to
avoid the pDDI or to reduce the risk for an ADR by other
means.
Despite the fact that we could show positive effects in
terms of recognition of pDDIs and implementation of
recommendations, we are convinced that in hospitalized
patients, interventions regarding pDDIs should ideally be
provided at the point of prescription. In clinical practice,
DDI alert programs should be integrated into the CPOE
system. Health professionals with specific knowledge in
recognition and management of pDDIs and other medica-
tion errors should survey the overriding of alerts, and
interventions should be executed if overridden alerts are
deemed to be clinically relevant [27, 39]. As modifications
in medication shortly before hospital discharge are com-
mon, a pDDI check at discharge can also be recommended.
The importance of a DDI check at discharge is also given
by the fact that checks for DDIs are much more difficult to
perform in ambulatory patients [10, 17].
Limitations
Clinically manifest DDIs were not investigated in this
study. Therefore, we use the expression “potential” DDI.
Data about negative clinical outcomes caused by DDIs are
rare, but some retrospective studies have been published
[40, 41] showing increased risks for ADRs for patients with
drug prescriptions containing pDDIs. Intervention studies
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should be performed to investigate whether good clinical
management of pDDIs can reduce drug-related morbidity
and/or mortality.
Conclusions
The management of clinically relevant pDDIs can be
improved by a good collaboration between health profes-
sionals involved in drug therapy. Providing substantiated
recommendations to the treating physicians appears to be
rewarding in the case of pDDIs, as most recommendations
are accepted and implemented and are still in place 1 year
after hospital discharge.
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